ReviewFrontiers in immunology2026
Synthetic double-stranded RNA in antiviral immunity and vaccine adjuvant: insights into poly(I:C) and poly(A:U).
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic double-stranded RNA (dsRNA) analogues function as viral mimetics that activate innate immune signaling pathways critical for antiviral defense and the induction of adaptive immunity. Among dsRNA analogues, polyinosinic:polycytidylic acid [poly(I:C)] and polyadenylic:polyuridylic acid [poly(A:U)] have been extensively studied for their immunostimulatory properties and potential as vaccine adjuvants. This review examines how host pattern-recognition receptors sense synthetic dsRNA and explains the rationale for using poly(I:C) and poly(A:U) as representative dsRNA analogues with distinct structural and signaling properties. We compare their antiviral and adjuvant activities, emphasizing differences and commonalities in receptor engagement, downstream signaling, immunogenicity, and safety. Finally, we address emerging applications, translational challenges, and future directions for the rational design and clinical development of dsRNA-based immunomodulators in antiviral immunity and vaccine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.